PRPH
ProPhase Labs, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$0.01
−17.09%Next report
Analyst consensus
- Next report date
- Nov 16, 2026
- EPS estimate
- $2.05
- Revenue estimate
- $12.0M
Latest reported
- Last report date
- Aug 19, 2026
- EPS actual
- -$0.22
- EPS estimate
- —
- Revenue actual
- $1.0M
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -24.5%
- Revenue beats (12Q)
- 2
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 19, 2026 | — | -$0.22 | — | $1.0M |
| Jun 30, 2026 | — | -$0.43 | — | $478.0K |
| Nov 19, 2025 | -$1.10 | -$1.60 | Miss -45.45% | $883.0K |
| Aug 13, 2025 | -$0.15 | -$0.11 | Beat 26.67% | $1.2M |
| May 20, 2025 | -$0.18 | -$0.12 | Beat 33.33% | $1.4M |
| Mar 31, 2025 | -$0.24 | -$0.51 | Miss -112.50% | -$2.5M |
| Aug 14, 2024 | -$0.08 | -$0.33 | Miss -312.50% | $2.5M |
| May 9, 2024 | -$0.28 | -$0.07 | Beat 75.00% | $3.6M |
| Nov 9, 2023 | -$0.20 | -$0.30 | Miss -50.00% | $8.4M |
| Aug 10, 2023 | -$0.14 | -$0.20 | Miss -42.86% | $13.2M |
| May 11, 2023 | -$0.10 | $0.03 | Beat 130.00% | $19.3M |
| Nov 10, 2022 | $0.15 | $0.06 | Miss -60.00% | $24.2M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 16, 2026